Irbesartan Tablets, USP, 75 mg, 90- count bottle, Rx only, Manufactured by: Jubilant Generics Ltd. Roorkee- 247661, India, Marketed by: Jubilant Cadista Pharmaceuticals Inc. Salisbury, MD 21801, USA, NDC 59746-447-90
Published August 3, 2022 · Recall initiated: July 18, 2022
Summary
FDA records drug Class II recall D-1294-2022, published August 3, 2022 and initiated July 18, 2022. Recalling firm: Jubilant Cadista Pharmaceuticals, Inc.; Status: Terminated; Reported quantity: 28,560 bottles; Lot: Lot #: IB120012A, IB120013A, IB120014A Exp. date 08/2022. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Failed Dissolution Specifications
What to do
Voluntary: Firm initiated · Letter
Get an email if IRBESARTAN has another recall
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Brand
- IRBESARTAN
- Manufacturer
- Jubilant Cadista Pharmaceuticals, Inc.
- Distributor
- Nationwide within the United States
- UPC
- 0359746447304
- Lot
- Lot #: IB120012A, IB120013A, IB120014A Exp. date 08/2022
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDAIrbesartan Tablets USP, 300 mg, 50 Tablets (5 x 10) Unit Dose per carton, Manufactured for: AvKARE, Pulaski,February 19, 2025
- FDAIrbesartan Tablets, USP, 150mg, 90- count bottles, Rx only, Manufactured by: Jubilant Generics Ltd. Roorkee-August 3, 2022
- FDAJuice Beauty, The Organic Solution, SPF 8, Joyful Lip Moisturizer, Hydratant pour les Levres, NET WT 0.15 ozAugust 3, 2022
- FDAInsulin Glargine (Insulin glargine-yfgn) Injection, 100 units/mL (U-100), 3 mL prefilled pens (NDCAugust 3, 2022
- FDAIrbesartan Tablets USP, 150 mg a) 30 count (NDC 68180-411-06) and b) 90 count (NDC 68180-411-09) bottles, RxNovember 10, 2021
- FDAIrbesartan Tablets USP, 75 mg a) 30 count (NDC 68180-410-06) and b) 90 count (NDC 68180-410-09) bottles, RxNovember 10, 2021
Questions about this recall
Was Irbesartan Tablets, USP, 75 mg, 90- count bottle, Rx only, Manufactured by: Jubilant Generics Ltd. Roorkee- 247661, India, Marketed by: Jubilant Cadista Pharmaceuticals Inc. Salisbury, MD 21801, USA, NDC 59746-447-90 recalled?
Yes. FDA published recall D-1294-2022 on August 3, 2022. Reported hazard: Failed Dissolution Specifications
What should I do if I have this product?
Voluntary: Firm initiated · Letter
How do I know if my unit is part of the recall?
Compare your product details with the notice. Brand: IRBESARTAN. UPC: 0359746447304.